The Genomic Landscape of Prostate Cancer

International Journal of Molecular Sciences

Lien Spans³  Liesbeth Clinckemalie³  Christine Helsen³  Dirk Vanderschueren²  Steven Boonen⁴  Evelyne Lerut¹  Steven Joniau⁵ 

[1] Division of Translational Cell and Tissue Research, Department of Imaging and Pathology, University of Leuven, Minderbroedersstraat 12 blok q, P.O. Box 1032, 3000 Leuven, Belgium; E-Mail:;Division of Clinical and Experimental Endocrinology, Department of Clinical and Experimental Medicine, University of Leuven, Campus Gasthuisberg, Herestraat 49, P.O. Box 902, 3000 Leuven, Belgium; E-Mail:;Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, University of Leuven, Campus Gasthuisberg, Herestraat 49, P.O. Box 901, 3000 Leuven, Belgium; E-Mails:;Division of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Leuven, Campus Gasthuisberg, Herestraat 49, P.O. Box 7003, 3000 Leuven, Belgium; E-Mail:;Division of Screening, Diagnostics and Biomarkers, Department of Development and Regeneration, University Hospitals Leuven, Campus Gasthuisberg, Herestraat 49, P.O. Box 7003, 3000 Leuven, Belgium; E-Mail:

关键词: prostate cancer;    next-generation sequencing;    copy number changes;    gene fusions;    long non-coding RNAs;    methylation;    microRNAs;    single nucleotide polymorphisms;    single nucleotide variants;   

DOI  :  10.3390/ijms140610822

来源: mdpi

【 摘 要 】

By the age of 80, approximately 80% of men will manifest some cancerous cells within their prostate, indicating that prostate cancer constitutes a major health burden. While this disease is clinically insignificant in most men, it can become lethal in others. The most challenging task for clinicians is developing a patient-tailored treatment in the knowledge that this disease is highly heterogeneous and that relatively little adequate prognostic tools are available to distinguish aggressive from indolent disease. Next-generation sequencing allows a description of the cancer at an unprecedented level of detail and at different levels, going from whole genome or exome sequencing to transcriptome analysis and methylation-specific immunoprecipitation, followed by sequencing. Integration of all these data is leading to a better understanding of the initiation, progression and metastatic processes of prostate cancer. Ultimately, these insights will result in a better and more personalized treatment of patients suffering from prostate cancer. The present review summarizes current knowledge on copy number changes, gene fusions, single nucleotide mutations and polymorphisms, methylation, microRNAs and long non-coding RNAs obtained from high-throughput studies.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland